The disclosure comes as another of Arcus's TIGIT trials flops.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
The group eyes a broader use than Immunocore’s Kimmtrak.
A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.
An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
Duelling pivotal trials of anti-TROP2 ADCs should yield their first data imminently.
A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.